Theranostics 2019; 9(16):4595-4596. doi:10.7150/thno.36746 This issue

Erratum

Site-specific stabilization of minigastrin analogs against enzymatic degradation for enhanced cholecystokinin-2 receptor targeting: Erratum

Maximilian Klingler1, Clemens Decristoforo1, Christine Rangger1, Dominik Summer1, Julie Foster2, Jane K Sosabowski2, Elisabeth von Guggenberg1 Corresponding address

1. Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria
2. Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Citation:
Klingler M, Decristoforo C, Rangger C, Summer D, Foster J, Sosabowski JK, von Guggenberg E. Site-specific stabilization of minigastrin analogs against enzymatic degradation for enhanced cholecystokinin-2 receptor targeting: Erratum. Theranostics 2019; 9(16):4595-4596. doi:10.7150/thno.36746. Available from https://www.thno.org/v09p4595.htm

File import instruction

Corrected-article in Theranostics, Volume 8, 2896

 

In our paper [1] unfortunately an error occurred in Figure 1. We therefore would like to provide the readers with the corrected figure and apologize for this inconvenience.

 Figure 1 

Structure of A) DOTA-MG11, B) DOTA-MGS1, C) DOTA-MGS2, D) DOTA-MGS3, E) DOTA-MGS4; R = DOTA-DGlu-Ala-Tyr-Gly.

Theranostics Image

(View in new window)

References

1. Klingler M, Decristoforo C, Rangger C, Summer D, Foster J, Sosabowski JK, von Guggenberg E. Site-specific stabilization of minigastrin analogs against enzymatic degradation for enhanced cholecystokinin-2 receptor targeting. Theranostics. 2018;8(11):2896-2908

Author contact

Corresponding address Corresponding author: E-mail: elisabeth.von-guggenbergac.at; Tel: +4351250480960; Fax: +435125046780960


Published 2019-6-19